Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $0.4239 is 14.54% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 0.435||$ 3.12|
|Low:||$ 0.38||$ 0.3701|
Company Description (as filed with the SEC)
On December 14, 2017, the Company's Board of Directors approved a change in our fiscal year end from June 30 to December 31, effective December 31, 2017. The transition period for this Transition Report on Form 10-K is for the six months ended December 31, 2017 (which we sometimes refer to in the Transition Report as the "transition period"). In this Transition Report, our fiscal years are identified according to the calendar year in which they historically ended (e.g., the fiscal years ended June 30, 2017 is referred to as "fiscal 2017" and June 30, 2016 is referred to as "fiscal 2016" as if we had not changed our fiscal year to a calendar year on December 14, 2017 (effective December 31, 2017)). Overview We are a biopharmaceutical company (incorporated in Delaware, May 15, 2013) focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus ("HBV") infection. ... More ...
Nasdaq Official Price
Dec. 13, 2018
Dec. 13, 2018